To determine whether supplementation of anti-phospholipase A 2 antibody (aPLA 2 ) would alter voluntary DMI, feed efficiency (FE), acute-phase protein concentration, and blood differentials (BD) due to a change in diet from a forage-based to a grain-based diet, individual daily DMI was measured on 80 crossbred steers during a 141-d period. On d 0, steers were blocked by BW and randomly assigned to receive a growing forage diet containing 1) no additive (CON; n = 20), 2) inclusion of 30 mg of monensin and 8.8 mg of tylosin per kg of diet DM (MT; n = 20), 3) inclusion of an aPLA 2 supplement at 0.4% of the diet DM (0.4% aPLA 2 ; n = 20), and 4) inclusion of an aPLA 2 supplement at 0.2% of the diet DM (0.2% aPLA 2 ; n = 20). On d 60, steers were transitioned into a grain-based diet (90% concentrate) over a 21-d "step-up" period while continuing to receive their supplement treatments and were maintained on the high-grain diet until the end of the trial on d 141. On d 0, 60, 81, and 141, individual shrunk BW was recorded. Blood samples were collected on d 60, 63, 65, 67, 70, 72, 74, 77, 79, 81, and 84 for determination of concentration of plasma ceruloplasmin, haptoglobin, and BD. During the growing forage-diet period, steers from the 0.2% aPLA 2 and 0.4% aPLA 2 treatments had lower (P < 0.05) residual feed intake (RFI; -0.12 ± 0.13 and -0.22 ± 0.13 kg/d, respectively) than steers from the CON treatment (0.31 ± 0.13 kg/d). During the grain-based diet period, the 0.2% aPLA 2 (-0.12 ± 0.10 kg/d), 0.4% aPLA 2 (0.36 ± 0.10 kg/d), and MT (0.10 ± 0.10 kg/d) steers had greater (P = 0.04) RFI than CON steers (-0.37 ± 0.10 kg/d). During the transition phase, white blood cell counts were greater (P = 0.04) for the 0.2% aPLA 2 treatment (13.61 × 10 3 ± 0.42 × 10 3 cells/μL) than the 0.4% aPLA 2 and MT treatments (12.16 × 10 3 ± 0.42 × 10 3 and 12.37 × 10 3 ± 0.42 × 10 3 cells/μL, respectively) and concentrations of lymphocytes also were greater (P = 0.01) for the 0.2% aPLA 2 treatment (7.66 × 10 3 ± 0.28 × 10 3 cells/μL) than the 0.4% aPLA 2 and MT treatments (6.71 × 10 3 ± 0.28 × 10 3 and 6.70 × 10 3 ± 0.28 × 10 3 cells/μL, respectively). Concentrations of plasma ceruloplasmin and haptoglobin were reduced (P < 0.05) for CON compared to aPLA 2 steers (22.2 ± 0.83 vs. 24.4 ± 0.83 mg/dL and 0.18 ± 0.05 vs. 0.26 ± 0.05 mg/mL, respectively). Supplementation of aPLA 2 improved FE of steers fed a forage-based growing diet but not when feeding grain-based diets. The 0.4% aPLA 2 and MT treatments had decreased white blood cell counts and concentration of lymphocytes during the transition period compared to the 0.2% aPLA 2 treatment, and CON steers had reduced concentrations of plasma ceruloplasmin and haptoglobin during the diet transition phase.
INTRODUCTION
Lipopolysaccharides (LPS) are commonly present in rumen fluid and can translocate into the bloodstream and activate the acute phase response (APR), especially under immunological stress and ruminally acidotic conditions (Andersen et al., 1994;  Effects of anti-phospholipase A 2 antibody supplementation on dry matter intake feed efficiency, acute phase response, and blood differentials of steers fed forage-and grain-based diets 1 Gozho et al., 2007; Emmanuel et al., 2007 Emmanuel et al., , 2008 ; Khafipour et al., 2009; Ametaj et al., 2009; Dong et al., 2011) . Feeding monensin and tylosin modifies the ruminal microflora, with improved digestive efficiency of cattle consuming high-grain diets, due to increased ruminal concentration of propionic acid, improved feed efficiency (FE) and ADG, reduced DMI, and lower incidence of acidosis and liver abscesses in cattle (Burrin and Britton, 1986; Galyean et al., 1992; Meyer et al., 2009; Nagaraja et al., 1985; Nagaraja and Titgemeyer, 2007; Richardson et al., 1976) . However, antimicrobial resistance is a growing public issue and the use of antibiotics as growth promotants for beef cattle seems to be subjected to future limitations and more restricted regulations (Galyean et al., 2011) .
Recently, an egg-derived antibody against intestinal secreted phospholipase A 2 (sPLA 2 ), anti-phospholipase A 2 (aPLA 2 ; Cook and Trott, 2010) , was developed to regulate the intestinal inflammatory response and the negative effects of the activation of the APR on animal growth and FE, and it has been successfully used as a feed additive for poultry, swine, and fish, with improved FE and growth (Yang et al., 2003; Cook, 2004 Cook, , 2011 Schwartz et al., 2006; Barry and Yang, 2008) . Therefore, the potential exists that steers consuming aPLA 2 may have decreased inflammatory response due to a transition into high-grain diets and, consequently, enhanced performance and improved FE. The objectives of this study were to determine whether supplementation of aPLA 2 would alter animal performance, voluntary DMI, FE, plasma concentration of acute-phase protein, and blood differentials (BD) of steers transitioned from a high-forage into a high-grain diet.
MATERIALS AND METHODS
All procedures for the study conducted at the North Florida Research and Education Center (NFREC; Marianna, FL) were approved by the University of Florida Institute of Food and Agricultural Sciences Animal Research Committee. Before initiation of this experiment, using a bioassay described by Cook and Trott (2010) , we determined whether active aPLA 2 antibody was present in the lower digestive tract on duodenal digesta samples collected from duodenal cannulated steers receiving a forage-based diet with either an aPLA 2 supplement or no supplement. The results (data not shown) demonstrated the presence of active aPLA 2 antibody within the duodenal samples of the steers receiving the aPLA 2 antibody supplement.
Animals and Treatments
Eighty cross-bred steers were allocated in group pens (108 m 2 /pen; 8 pens with 10 animals each) at the NFREC Feed Efficiency Facility (FEF). Individual daily DMI was measured using the GrowSafe system (GrowSafe Systems Ltd., Alberta, Canada). Each pen in the FEF was equipped with 2 GrowSafe feed bunks. Steers were blocked by BW (low and high) and then randomly assigned to pens to receive treatments. A 14-d period of adaptation to facilities and diets preceded the initiation of the 141-d trial. Shrunk BW (16 h following removal from feed) was measured on d 0, before initiation of diet change on d 60, immediately following diet change on d 81, and at the conclusion of the study on d 141.
Following the adaptation period, the experiment was divided in 3 phases (Fig. 1) . In Phase I, steers were fed a growing diet (0.80 Mcal NEg/kg of DM and 13% CP) comprising 69% concentrate, 31% bermudagrass hay, and a vitamins and minerals supplement containing the following treatments: 1) no additive (CON; n = 20), 2) inclusion of 30 mg of monensin and 8.8 mg of tylosin per kg of diet DM (MT; n = 20), 3) inclusion of an aPLA 2 supplement at 0.2% of the diet DM (0.2% aPLA 2 ; n = 20; aPLA 2 dried whole-egg antibody supplement; BIG BEEF; Aova Technologies, Madison, WI; Cook and Trott, 2010) , and 4) inclusion of an aPLA 2 supplement at 0.4% of the diet DM (0.4% aPLA 2 ; n = 20; BIG BEEF; Aova Technologies; Cook and Trott, 2010) . In Phase II, on d 60, all steers were transitioned into a grain-based diet using a 21-d "stepup" period with 3 steps from 69 to 75 (step 1), 85 (step 2), and 90% concentrate (step 3). In Phase III, on d 81, all steers received a 90% concentrate diet (74% cracked corn; 1.32 Mcal NEg/kg of DM and 11.4% CP) for 60 d until the conclusion of the experiment on d 141. A soybean meal-based premix containing 0.2 or 0.4% of aPLA 2 or no antibody was mixed with diets at 1% of the diet DM. In addition, 2 pelleted supplements were included at 5% of the diet DM to deliver either no antibiotics (CON and all aPLA 2 -containing diets) or MT. Steers were maintained in the same group pens throughout the 141-d trial. The nutrient content of all diets are presented on Table 1 .
On d 0 and 141, ultrasound was used to determine fat thickness (BF) and longissimus dorsi muscle area (REA) using an Aloka real-time ultrasound scanner (3.5-MHz linear array transducer Aloka 500V; Corimetrics Medical Systems, Inc., Wallingford, CT) and image capturing software. Scanning was performed on the right side of each animal, between the 12th and 13th ribs. There were 2 measurements taken per animal at each scanning session. Final BF and REA values were calculated as the average between the 2 measurements recorded.
Blood Collection and Analyses
Blood samples from each steer were collected from the jugular vein into 10-mL evacuated glass vials containing 143 IU of sodium heparin (Vacutainer; Becton Dickinson Inc., Franklin Lakes, NJ) on Days 0, 3, 5, 7, 10, 12, 14, 17, 19 , and 21 relative to the initiation of the Phase II "step-up" period. Blood samples were immediately placed on ice and centrifuged at 1,500 × g at 4°C for 15 min. The plasma was transferred by pipette into polypropylene vials (12 by 75 mm; Fisherbrand; Thermo Fisher Scientific Inc., Waltham, MA) and stored at -20°C until further analysis.
A spectrophotometer (ThermoSpectronic Genesys 20; Thermo Fisher Scientific Inc.) was used to determine plasma ceruloplasmin concentration. The plasma ceruloplasmin oxidase activity was measured in duplicate samples using colorimetric procedures as described in the literature (Demetriou et al., 1974) . Concentrations of ceruloplasmin were expressed as milligrams/deciliter (King, 1965) . The intra-and interassay CV for ceruloplasmin were 6.0 and 10.4%, respectively. A microplate spectrophotometer (PowerWave 340; BioTek Instruments, Inc., Winooski, VT) was used to determine concentrations of plasma haptoglobin in duplicate samples by measuring haptoglobin/hemoglobin 
HF
Step 1 Step 2 HG ---% DM basis--- Step 1 = 75% concentratemg/kg diet fed for 7 d; Step 2 = 85% concentrate diet fed for 7 d; HG = high-grain diet fed for 70 d during Phase III.
2 A soybean hull premix containing inclusion of an anti-phospholipase A 2 antibody (aPLA 2 ) supplement at 0.2% of the diet DM, inclusion of an aPLA 2 supplement at 0.4% of the diet DM, or no antibody, which was mixed in the diet according to treatments.
3 A pelleted supplement containing (DM basis): 18% CP, 13.8% Ca, 0.53% P, 9.5% salt, 0.54% Mg, 1.33% K, 0.22% S, 93 mg/kg Co, 224 mg/kg Cu, 54 mg/kg I, 375 mg/kg Fe, 694 mg/kg Mn, 8 mg/kg Se, and 540 mg/kg Zn. 4 Formulated to supply either no feed additive or 30 mg of monensin plus 8.8 mg of tylosin per kg of diet DM, according to treatments.
complexing by the estimation of differences in peroxidase activity as described previously (Makimura and Suzuki, 1982) and results are expressed as arbitrary units from the absorption reading at 450 nm × 100. The intra-and interassay CV for haptoglobin were 7.0 and 11.3%, respectively.
Blood differentials, total red blood cell count (RBC), hematocrit (HCT), hemoglobin (HGB), total white blood cell count (WBC), neutrophils, lymphocytes, neutrophil:lymphocyte ratio (N:L), monocytes, eosinophils, and total platelets count were assessed using a hematology cell counter (IDEXX ProCyte DX Hematology Analyzer; IDEXX Laboratories, Westbrook, ME) and individual whole blood samples collected following the same sampling schedule described above. Blood samples were collected from the jugular vein into 2.0-mL polypropylene evacuated tubes containing 3.6 mg of K 2 EDTA (BD Hemogard; Becton Dickinson Inc.) and immediately stored on ice until analysis; all samples were analyzed within 8 h of collection.
Feed Sample Collection and Analysis
Representative samples of each treatment total mixed ration diet were taken before feeding at 28-d intervals throughout the 141-d trial. All samples were bagged and frozen immediately after collection until drying. All feed samples analyzed for nutritive values were dried at 55°C for 48 h in a forced-air oven. At the conclusion of the drying period, all samples were ground in a Wiley mill (Arthur H. Thomas Company, Philadelphia, PA) using a 1.0-mm screen. After grinding, samples were composited for analysis on an equal weight basis. The composited samples were analyzed for DM, CP, TDN, ADF, NDF, Ca, and P in duplicate by a commercial laboratory (Dairy One Forage Laboratory, Ithaca, NY).
Statistical Analysis
Individual steer ADG was determined by the difference between the shrunk BW at the end and the beginning of each phase divided by the number of days on trial. The G:F was computed as the ratio of ADG to daily DMI. Residual feed intake (RFI) was calculated as actual DMI minus expected DMI, with expected DMI derived from the regression of actual DMI on ADG and midtest metabolic BW using the regression equations provided by the GLM procedure of SAS (SAS Inst. Inc., Cary, NC).
Animal was the experimental unit. The MIXED procedure of SAS was used to identify differences in BW, ADG, average daily DMI, G:F, RFI, BF, and REA. The statistical model included treatment and pen within treatment. The repeated measures statement of the MIXED procedure of SAS was used to analyze differences in concentrations of haptoglobin and ceruloplasmin, BD, and daily DMI during the Phase II "step-up" period. The statistical model included treatment, day, and treatment × day interaction, with day as the repeated measure (d 0, 3, 5, 7, 10, 12, 14, 17, 19, and 21) , animal as the subject, and block (low and high BW) as the random effect. The decrease in DMI (DECDMI) immediately after each change in diet during Phase II was analyzed using the repeated measures statement of the MIXED procedure of SAS. The statistical model included treatment, day, and treatment × day interaction, with day as the repeated variable (d 1, 8, and 15), animal as the subject, and block (low and high BW) as the random effect.
The CONTRAST function of the MIXED procedure of SAS was used to conduct orthogonal contrasts between the 0.2% aPLA 2 and 0.4% aPLA 2 treatments (0.2/0.4), both aPLA 2 treatments combined against the MT treatment (aPLA 2 /MT), and both aPLA 2 treatments combined against the CON treatment (aPLA 2 /CON) on daily DMI, concentrations of ceruloplasmin and haptoglobin, and BD during Phase II. The statistical model included treatment, day, and the treatment × day interaction. The GLM procedure of SAS was used to assess the correlation between concentrations of haptoglobin and ceruloplasmin with DMI during Phase II on d 0, 3, 5, 7, 10, 12, 14, 17, 19 , and 21. Statistical differences were reported at P < 0.05 and tendencies were identified when P < 0.10, with means being reported as least squares means means ± SEM.
RESULTS AND DISCUSSION
High-concentrate diets have been linked to the activation of the APR in cattle (Emmanuel et al., 2008; Ametaj et al., 2009) , which may negatively affect animal growth and FE as a result of decreased DMI, wasting of skeletal muscle, and lipolysis (Johnson, 1997; Cook, 2011) . However, in the current experiment, there were no statistical differences among treatments in measurements of performance and FE (Table 2) . No treatment differences were detected in BW on d 0 (212.0 ± 4.0 kg; P = 0.94) and on d 141 (388.0 ± 5.1 kg; P = 0.79), ADG (1.25 ± 0.02 kg/d; P = 0.33), BF on d 0 (0.96 ± 0.04 cm; P = 0.89) and on d 141 (1.43 ± 0.11 cm; P = 0.73), REA on d 0 (25.3 ± 3.4 cm 2 ; P = 0.49) and on d 141 (46.4 ± 2.6 cm 2 ; P = 0.51), G:F (0.18 ± 0.01; P = 0.98), average daily DMI (7.1 ± 0.1 kg; P = 0.43), and RFI (-1.25 ± 0.06 kg/d; P = 0.61).
Animal performance and FE data during Phase I are summarized in Table 3 . There were no differences on BW at d 60 (259.0 ± 4.4 kg; P = 0.84) and G:F (0.11 ± 0.01; P = 0.16) among treatments. However, there was a tendency (P = 0.08) for the MT treatment to have greater ADG compared to the 0.2% aPLA 2 treatment, whereas the CON and 0.4% aPLA 2 treatments were intermediate. Feeding monensin and tylosin improves DM digestive efficiency of cattle, increasing ruminal concentrations of propionic acid and decreasing concentrations of acetate and butyrate (Richardson et al., 1976; Beckett et al., 1998) , increasing glucose supply to the animal and thus improving FE, reducing DMI, and improving ADG of growing and finishing cattle (Duffield et al., 2012) .
Similar to the results from previous experiments conducted by our laboratory (Mercadante et al., 2015) , aPLA 2 supplementation tended to reduce daily DMI and significantly reduced RFI compared to CON steers, improving FE of steers fed forage-based diets during Phase I. Daily DMI tended (P = 0.07) to be lower for both the 0.2% aPLA 2 and 0.4% aPLA 2 treatments compared to the CON treatment, with the MT treatment being intermediate. Steers from both aPLA 2 treatments had lower RFI than CON steers (P < 0.05). Steers in the 0.4% aPLA 2 treatment had the lowest RFI, and MT steers had intermediate RFI values compared to other treatments. Regulation of the intestinal inflammatory response by blocking intestinal sPLA 2 reduces the nutrient and energy costs of the immune intestinal barrier, therefore reducing the maintenance requirements and DMI of the animal, with an overall improvement in FE (Cook, 2011) , which may explain the improvements in RFI when aPLA 2 was supplemented.
Performance and FE data during Phase II are summarized in Table 4 . There were no differences among treatments on BW on d 81 (297.0 ± 10.3 kg; P = 0.46), ADG (1.89 ± 0.32 kg/d; P = 0.17), and G:F (0.26 ± 0.04; P = 0.47) during Phase II. However, similar to Phase I, average daily DMI was lower (P = 0.02) for 0.4% aPLA 2 steers compared to MT and CON steers, and daily DMI for steers on 0.2% aPLA 2 was intermediate.
Daily DMI was impacted by diet changes during Phase II. Supplementation of aPLA 2 and monensin and tylosin reduced DMI of steers during the transition to grain-based diets. Using contrast analysis to assess differences in daily DMI during Phase II, there were no differences (P = 0.18) in daily DMI between the aPLA 2 treatments (data not shown). However, when comparing both aPLA 2 treatments combined against the CON treatment (Fig. 2) and both aPLA 2 treatments plus the MT treatment combined against CON (Fig. 3) , CON steers had greater (P < 0.0001) daily DMI during Phase II. Dry matter intake was decreased (day effect, P < 0.0001) on the day after diet change (d 1, 8, and 15) across all treatments. The mean DECDMI on the day after change in diets were lesser (P = 0.03) for the MT compared with CON steers, and both aPLA 2 treatments were intermediate (Table 4) .
A treatment × day effect (P < 0.001) was also detected for DECDMI (Fig. 4) . On d 1, CON steers had the greatest DECDMI compared to 0.2% aPLA 2 and MT steers. There was a tendency (P = 0.06) for the 1 0.2% aPLA 2 = inclusion of an anti-phospholipase A 2 antibody (aPLA 2 ) supplement at 0.2% of the diet DM; 0.4% aPLA 2 = inclusion of an aPLA 2 supplement at 0.4% of the diet DM; MT = inclusion of 30 mg of monensin and 8.8 mg of tylosin per kg of diet DM; CON = no additive.
2 Shrunk BW (16-h separation from feed).
3 Average daily gain calculated as the difference between BW on d 0 and on d 141 divided by the number of days on trial. 4 Average daily DMI during the 141-d trial.
5 RFI = residual feed intake.
6 BF = fat thickness (measured between the 12th and 13th ribs by ultrasonography).
7 REA = longissimus dorsi muscle area (measured between the 12th and 13th ribs by ultrasonography). a,b Significant differences of least squared means within a row (P < 0.05).10.2% aPLA 2 = inclusion of an anti-phospholipase A 2 antibody (aPLA 2 ) supplement at 0.2% of the diet DM; 0.4% aPLA 2 = inclusion of an aPLA 2 supplement at 0.4% of the diet DM; MT = inclusion of 30 mg of monensin and 8.8 mg of tylosin per kg of diet DM; CON = no additive.
3 Average daily gain calculated as the difference between BW on d 0 and on d 60 divided by the number of days on trial. 4 Average daily DMI during the 60 d of Phase I.
aPLA 2 treatments to have lesser DECDMI than the CON treatments, with MT steers having intermediate DECDMI, on d 8. However, on d 15, DECDMI was greater (P < 0.01) for both aPLA 2 treatments than the MT treatment and CON steers had reduced DECDMI compared to 0.2% aPLA 2 steers. The overall lower DECDMI of MT steers is likely a reflection of the inhibition of gram-positive bacteria in the rumen (Richardson et al., 1976) during the transition to grain-based diets, increasing ruminal propionate concentration and improving ruminal function, decreasing the negative impacts of the ruminal adaptation to higher concentrate contents of the diets on DMI and animal performance (Nagaraja et al., 1985) . The effects of aPLA 2 supplementation on DECDMI during the "step-up" phase were inconsistent (Fig. 2) . In an in vitro fermentation study using low-concentrate and high-concentrate substrates, aPLA 2 supplementation had no effects on pH and VFA production and acetate to propionate ratio (Mercadante et al., 2015) , suggesting that modifying rumen fermentation is more beneficial to cattle consuming high-concentrate diets rather than targeting the activation of the immune system.
Animal performance data during Phase III are summarized in Table 5 . Supplementation of monensin and tylosin have been successfully used to decrease the risk of acidosis in cattle consuming high-grain diets, due to reduction in lactic acid concentration in the rumen, reducing the negative impact of acidosis on ruminal function (Nagaraja et al., 1985; Burrin and Britton, 1986; Nagaraja and Titgemeyer, 2007) . Monensin also increases ruminal concentration of propionic acid, increasing hepatic pro- duction of glucose (Richardson et al., 1976; Bergen and Bates, 1984) and thus improving animal performance and FE of cattle (Duffield et al., 2012) . However, in the current experiment, there were no differences in BW at d 141, ADG, average daily DMI, and G:F among treatments. Residual feed intake was greater (P = 0.04) for the 0.4% aPLA 2 treatment compared to the CON treatment. Steers in the 0.4% aPLA 2 treatment had the greatest RFI (0.36 ± 0.10 kg/d) and CON steers had the lowest RFI (-0.37 ± 0.10 kg/d), with 0.2% aPLA 2 and MT steers remaining intermediate (-0.12 ± 0.10 and 0.10 ± 0.10 kg/d, respectively). Feeding high-grain diets reduced ruminal pH and facilitated the development of acidosis and rumenitis (Nagaraja and Titgemeyer, 2007) . Egg antibodies were shown to retain over 85% of their antirotavirus neutralizing activity at a pH 2 for 1 h, even though the antibody binding capacity was reduced by 50% (Cook and Trott, 2010) . However, the effects of long exposures to lower pH, such as the rumen when feeding high-grain diets, on egg antibody function have not been reported. Perhaps the failure of aPLA 2 supplementation to improve FE during Phase III is a result of the denaturation of the antibody due to exposure of lower pH in the rumen, directly affecting the quantity of active antibody passing through the rumen into the intestine and its capacity to block the intestinal inflammatory response, thereby alleviating the negatives effects of the activation of the immune system over animal performance.
Blood differentials and acute-phase protein data are summarized in Table 6 . Although differences among treatments were observed, mean BD concentration were within the normal range for cattle (Kahn and Line, 2010) and therefore do not support the establishment of a systemic inflammatory response due to transition into highgrain diets. There were no treatment effects on mean RBC (8.96 × 106 ± 0.30 × 106 cells/μL; P = 0.23), HCT (34.58 ± 0.82%; P = 0.27), HGB (11.58 ± 0.46 g/dL; P = 0.46), neutrophils (3.56 × 10 3 ± 0.23 × 10 3 cells/μL; P = 0.21), N:L (0.53 ± 0.03; P = 0.84), monocytes (2.42 × 10 3 ± 0.71 × 10 3 cells/μL; P = 0.82), eosinophils (0.22 × 10 3 ± 0.04 × 10 3 cells/μL; P = 0.64), and platelets (406.9 ± 34.2; P = 0.31). However, WBC was greater (P = 0.04) for the 0.2% aPLA 2 treatment (13.61 × 10 3 ± 0.42 × 10 3 cells/μL) than the 0.4% aPLA 2 and MT treatments (12.16 × 10 3 ± 0.42 × 10 3 and 12.37 × 3 ± 0.42 × 10 3 cells/μL, respectively), with CON being intermediate (12.87 × 10 3 ± 0.42 × 10 3 cells/μL). The mechanism by which a lower dose of aPLA 2 can increase WBC and lymphocyte concentration is unclear. Concentrations of lymphocytes also were greater (P = 0.01) for the 0.2% aPLA 2 treatment (7.66 × 10 3 ± 0.28 × 10 3 cells/μL) than the 0.4% aPLA 2 and MT treatments (6.71 × 10 3 ± 0.28 × 10 3 and 6.70 × 10 3 ± 0.28 × 10 3 cells/μL, respectively), with the CON treatment being intermediate (7.11 × 10 3 ± 0.28 × 10 3 cells/μL). Although not present in our experiment, transition from forage-to grain-based diets has been shown to activate the APR of cattle (Berry et al., 2004; Ametaj et al., 2009 ) through the development of acidosis and rumenitis with increased concentrations of LPS in the rumen fluid and translocation of LPS to the bloodstream (Nagaraja and Titgemeyer, 2007; Emmanuel et al., 2007 Emmanuel et al., , 2008 .
No differences in mean concentrations of plasma ceruloplasmin and haptoglobin among treatments during Phase II were detected (Table 6 ). There was a day effect (P < 0.01) for concentrations of both haptoglobin and ceruloplasmin in Phase II, indicating that steers experienced an APR during the transition to grain-based diets (Arthington et al., 2003; Emmanuel et al., 2007; Ametaj et al., 2009) . Concentrations of plasma ceruloplasmin peaked after each diet change, and there was a treatment × day effect (P = 0.01) during Phase II (Fig. 5) . On d 10, steers in the 0.4% aPLA 2 treatment had greater (P < 0.05) concentrations of ceruloplasmin than steers in the MT and CON treatments. On d 17, steers in the 0.2% aPLA 2 treatment had greater (P < 0.05) concentrations of ceruloplasmin than steers in the CON and MT treatments. On d 21, 0.2% aPLA 2 steers had greater (P = 0.02) concentrations of ceruloplasmin than CON steers, with MT and 0.4% aPLA 2 steers being intermediate. No treatment × day effect was detected (P = 0.46) for concentrations of plasma haptoglobin. However, concentrations of plasma haptoglobin tended to be lesser for the CON (P = 0.05) and MT (P = 0.09) treatments compared to the aPLA 2 treatment. Beef calves supplemented with aPLA 2 and submitted to transportation stress had reduced ceruloplasmin but not haptoglobin concentrations compared to nonsupplemented calves (Mercadante et al., 2015) . Transportation perhaps leads to a more acute a,b Significant differences of least squared means within a row (P < 0.05).
1 0.2% aPLA2 = inclusion of an anti-phospholipase A2 antibody (aPLA2) supplement at 0.2% of the diet DM; 0.4% aPLA2 = inclusion of an aPLA2 supplement at 0.4% of the diet DM; MT = inclusion of 30 mg of monensin and 8.8 mg of tylosin per kg of diet DM; CON = no additive.
stress compared to a gradual change in diet, which may explain the failure of aPLA 2 to reduce concentrations of ceruloplasmin and haptoglobin in the present study. However, the mechanism by which aPLA 2 may increase concentrations of ceruloplasmin and haptoglobin is unclear and needs further investigation. In addition, when combining all treatments, mean concentrations of plasma haptoglobin (Fig. 6 ) and ceruloplasmin ( Fig. 7) were negatively correlated (P < 0.001) with mean daily DMI during Phase II, in agreement with previous reports (Arthington et al., 2003; Cooke et al., 2009; Araujo et al., 2010; Mercadante et al., 2015) . Supplementation of aPLA 2 improved FE of steers fed a growing diet containing 31% forage (DM basis) but not when feeding grain-based diets. Steers from both aPLA 2 treatments and MT steers had reduced DMI during the 21-d transition period from foragebased to grain-based diets. In addition, CON steers had reduced concentrations of ceruloplasmin and tended to have reduced concentrations of haptoglobin during the transition to a grain-based diet compared to steers on the aPLA 2 and MT treatments. Mean daily DMI was negatively correlated with concentrations of plasma ceruloplasmin and haptoglobin. We conclude that aPLA 2 supplementation reduces DMI of steers consuming forage-based diets, without affecting performance, and therefore improves FE. However, the effects of aPLA 2 Table 6 . Blood differentials and concentrations of plasma acute-phase proteins of steers transitioned from a forage-based to grain-based diet over the 21-d "step-up" adaptation period during Phase II a,b Significant differences of least squared means within a row (P < 0.05). 1 RBC = red blood cell count; HCT = hematocrit; HGB = hemoglobin; WBC = white blood cell count; N:L = neutrophil:lymphocyte ratio. Units are presented as thousands of cells per microliter of blood and millions of cells per microliter of blood.
2 0.2% aPLA2 = inclusion of an anti-phospholipase A2 antibody (aPLA2) supplement at 0.2% of the diet DM; 0.4% aPLA2 = inclusion of an aPLA2 supplement at 0.4% of the diet DM; MT = inclusion of 30 mg of monensin and 8.8 mg of tylosin per kg of diet DM; CON = no additive.
3 Effect of treatment. 
